Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 01 Nov 2018 Status changed from recruiting to completed.
- 21 May 2015 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 21 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.